

UTILIZATION MANAGEMENT MEDICAL POLICY

POLICY: Enzyme Replacement Therapy – Naglazyme Utilization Management Medical Policy

- Naglazyme® (galsulfase intravenous infusion – BioMarin)

REVIEW DATE: 04/24/2024

OVERVIEW

Naglazyme, a human *N*-acetylgalactosamine 4-sulfatase, is indicated for **Mucopolysaccharidosis type VI** (Maroteaux – Lamy syndrome [MPS VI]).¹ It is produced in a Chinese hamster ovary cell line via recombinant DNA technology. The enzyme catalyzes the hydrolysis of the sulfate ester from the glycosaminoglycans, chondroitin 4-sulfate and dermatan sulfate. Naglazyme has been shown to improve walking and stair climbing capacity.

Disease Overview

MPS VI, or Maroteaux – Lamy syndrome, is a rare lysosomal storage disorder characterized by a deficiency of *N*-acetylgalactosamine 4-sulfatase (arylsulfatase B).^{2,3} The enzyme deficiency results in the accumulation of partially hydrolyzed dermatan sulfate and chondroitin 4-sulfate in lysosomes leading to the signs and symptoms of the disease.^{2,3} The onset, severity, and rate of progression of MPS VI is heterogeneous; however, most patients are severely affected with a rapidly progressive form.³ Clinical manifestations include coarse facial features, short stature, kyphoscoliosis, joint stiffness, pulmonary insufficiency, cardiac disease, hepatosplenomegaly, corneal clouding, and hernias.^{2,3} The definitive diagnosis of MPS VI is established by demonstrating deficient arylsulfatase B enzyme activity in leukocytes or fibroblasts, or by genetic testing.^{2,3} Definitive treatment of MPS VI consists of either enzyme replacement therapy with Naglazyme or hematopoietic stem cell transplantation. Due to the morbidity and mortality associated with hematopoietic stem cell transplantation, this therapy is typically reserved for patients who are intolerant of or do not respond to enzyme replacement therapy.²

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Naglazyme. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Naglazyme as well as the monitoring required for adverse events and long-term efficacy, approval requires Naglazyme to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Naglazyme is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Mucopolysaccharidosis Type VI (Maroteaux – Lamy Syndrome).** Approve for 1 year if the patient meets BOTH of the following (A and B):
 - A) The diagnosis is established by ONE of the following (i or ii):
 - i. Patient has a laboratory test demonstrating deficient *N*-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity in leukocytes or fibroblasts; OR
 - ii. Patient has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic arylsulfatase B (*ARSB*) gene variants; AND
 - B) Naglazyme is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

Dosing. Each dose must not exceed 1 mg/kg administered intravenously no more frequently than once weekly.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Naglazyme is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Naglazyme® intravenous infusion [prescribing information]. Novato, CA: BioMarin; April 2020.
2. Harmatz PR, Shediak R. Mucopolysaccharidosis VI: Pathophysiology, diagnosis and treatment. *Front Biosci.* 2017;22:385-406.
3. Vairo F, Federhen A, Baldo G, et al. Diagnostic and treatment strategies in mucopolysaccharidosis VI. *Appl Clin Genet.* 2015;8:245-255.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	04/12/2023
Annual Revision	Mucopolysaccharidosis Type VI (Maroteaux – Lamy Syndrome): Confirmation of a genetic mutation in the arylsulfatase B gene was revised to more specifically state, “genetic testing confirmation of biallelic pathogenic or likely pathogenic arylsulfatase gene variants”.	04/24/2024